Immunogenetics of drug-induced skin blistering disorders. Part II: Synthesis

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 779-816

  Bowman, Clive ^a   Delrieu, Olivier ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b 2PGX IS ^*  (United Kingdom)

Author keywords

EM; HLA; Hypersensitivity; Lyell syndrome; Maculopapular erythema; MHC; Pharmacogenetics; Rash; SJS; TEN

Indexed keywords

ANTIGEN; BW4 ANTIGEN; CYTOCHROME; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA C ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DR52 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 4; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLELE; APHTHOUS STOMATITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; BULLOUS SKIN DISEASE; CONJUGATION; CYTOTOXIC T LYMPHOCYTE; DRUG INDUCED DISEASE; DRUG INDUCED SKIN BLISTERING DISORDER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HASHIMOTO DISEASE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENETICS; IMMUNOPATHOGENESIS; NATURAL KILLER CELL; PHENOTYPE; RECURRENT FEVER; REVIEW; SIGNAL TRANSDUCTION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

BLISTER; CYTOCHROMES; DEMOGRAPHY; GENETIC VARIATION; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; HYPERSENSITIVITY; IMMUNOGENETIC PHENOMENA;

EID: 66949162934     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.23     Document Type: Review

References (367)

1. Bowman CE, Delrieu O: Immunogentics of drug-induced blistering disorders. Part I: Perspective. Pharmacogenomics 10(4), 601-621 (2009).
2. Pirmohamed M, Arbuckle J, Bowman C et al.: Investigation into the multi-dimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 8(12), 1661-1691 (2007).
3. Heeney JL, Dalgleish AG, Weiss RA: Origins of HIV and the Evolution of resistance to AIDS. Science 313, 462-468 (2006).
4. Kyttaris VC, Krishnan S, Tsokos GC: Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity 39(8), 705-709 (2006).
5. Clarck DW: Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29, 342-375 (1985).
6. Shear NH, Spielberg SP: Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J. Clin. Invest. 82, 1826-1832 (1988).
7. Chosidow O, Bourgault L, Roujeau JC: Drug rashes. What are the targets of cell-mediated cytotoxicity. Arch. Dermatol. 130, 627-629 (1994).
8. Evans EJ, Hene L, Sparks LM et al.: The T cell surface - how well do we know it. Immunity 19, 213-223 (2003).
9. Dutronc Y, Porcelli SA: The CDI family and T cell recognition of lipid antigens. Tissue Antigens 60, 337-353 (2002).
10. Karjalainen K: High sensitivity, low affinity - paradox of T-cell receptor recognition. Curr. Opin. Immunol. 6, 9-12 (1994).
11. Stroynowski I, Lindahl KF: Antigen presentation by non-classical class I molecules. Curr. Opin. Immunol. 6, 38-44 (1994).
12. Holgate ST: Genetic common ground between allergic and autoimmune disease: The role of cytotoxic T-lymphocyte antigen 4. J. Allergy Clin. Immunol. 114, 277-279 (2004),
13. Ingelfinger JR, Schwartz RS: Immunosuppression - the promise of specificity. N. Engl. J. Med. 353 (8), 836-839 (2005).
14. Tursen U, Tamer L, Eskandari G et al.: Glutathione S-transferase polymorphisms in patients with Behçet's disease. Arch. Dermatol. Res. 296(4), 185-187 (2004).
15. Ates NA, Tursen U, Tamer L et al.: Glutathione S-transferase polymorphisms in patients with drug eruption. Arch. Dermatol. Res. 295, 429-433 (2004).
16. Ollier W, Davies E, Snowden N et al.: Association ofhomozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro*/La autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum. 9, 1763-1764 (1996).
17. Freitas JP, Filipe P, Yousefi A et al.: Oxidative stress in Adamantiades-Behçet's disease. Dermatology 197, 343-348 (1998).
18. Rieder MJ, Uetrecht J, Sheaf NH, Spielberg SP: Synthesis and in vitro toxicity ofhydroxylamine metabolites of sulphonamides. J. Pharmacol. Exp. Ther. 244, 724-728 (1988).
19. Meekins CV, Sullivan TJ, Gruchalla RS: Immunochemical analysis of sulfonamide drug allergy: identification of sulfametnoxazole-sultrituted human serum proteins. J. Allergy Clin. Immunol. 94, 1017-1024 (1994).
20. Zemmour J, Ennis PD, Parham P, Dupont B: Comparison of the structure of HLA-B47 to HLA-B13 and its relationship to 21-hydroxylase deficiency. Immunogenetics 27(4), 281-287 (1988).
21. van der Linden SMD, van der Heijde DMD: Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr. Opin. Rheumatol. 12(4),263-268 (2000).
22. Marsh SGE, Parham P, Barber LD: The HLA Facts Book. London Academic Press, London, UK (2000).
23. Trachtenberg E, Korber B, Sollars C et al.: Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9(7), 928-935 (2003).
24. Goulder PJR, Klenerman P: Cytotoxic T lymphocytes and viral adaptation in HIV infection. Curr. Opin. HIV AIDS 1, 241-248 (2006).
25. Stern LJ, Brown JH, Jardetzky TS et al.: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
26. Lepage V, Douay C, Mallet C et al.: Erythema multiforme is associated to HLA-Aw33 and DRw53. Tissue Antigens 32(3),170-175 (1988).
27. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbasnazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
28. Nowak J, Mika-Witkowska, R, Polak M et al.: Allele and extended haplotype polymorphism of HLA-A, -C, -B, -DRB1 and -DQB1 loci in Polish population and genetic affinities to other populations. Tissue Antigens 71, 193-205 (2008).
29. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP: Uveitis and erythema nodosurn in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123(3), 714-718 (2002).
30. Smith MZ, Kent SJ: Genetic influences on HIV infection: implications for vaccine development. Sexual Health 2, 53-62 (2005).
31. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M: Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Human Immunology 64(5), 538-542 (2003).
32. Karimi O, Pega AS: Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev. Esp. Enferm. Dig. 97(8), 570-574 (2005).
33. Loewenthal R, Slomov Y, Gonzalez-Escribano MF et al.: Common ancestral origin ofpemphigus vulgaris in Jews and Spaniards: a study using microsatellite markets. Tissue Antigens 63, 326-334 (2004).
34. Li X, Ghandri N, Piancatelli D et al.: Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J. Transl. Med. 5, 22 (2007).
35. Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ, Dawkins RL: Ancestral haplotypes: conserved population MHC haplotypes. Hum. Immunol. 34, 242-252 (1992).
36. Hung S-I, Chung W-H, Chen YT: Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Drug Hypersensitivity. Pichler WJ (Ed.). Karger, Basel, Switzerland, 105-114 (2007).
37. Choukri F, Chakib A, Himmich H, Hue S, Caillat-Zucman S: HLA-B*51 and B*15 allefes confer predisposition to Behçet's disease in Moroccan patients. Hum. Immunol. 62(2), 180-185 (2001).
38. Roshna T, Thomas R, Nandakumar K, Banerjee MA: Case-control study on the association of human leukocyte antigen -A*9 and -B*15 allelcs with generalized aggressive periodontitis in an Indian population, J. Periodontol. 77(12), 1954-1963 (2006).
39. Farjadian S, Kiyanimanesh N, Abbaszadegan A, Lotfazar M: HLA class I gene polymorphism in Iranian patients with Papillon-Lefevre Syndrome. Iran. J. Immunol. 4(4), 241-245 (2007).
40. Aida K, Russomando G, Kikuchi M et al.: High frequency of MIC null haplotype (HLA-B48-MICA-de1-MICB*0107 N) in the Angaite Amerindian community in Paraguay. Immunogenetics 54, 439-441 (2002).
41. Falfon-Valencia R, Camarena A, Juarez A et al.: Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis. Hum. Genet. 118(2), 235-244 (2005).
42. Invernizzi P, Battezzati PM, Crosignani A et al.: Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J. Hepatol. 38(4), 401-406 (2003).
43. Pradhan VD, Devaraj JP, Shankarkumar U, Badakere SS: Autoimmune studies and HLA associations in SLE patients from Mumbai. Int. J. Hum. Genet. 4 (2), 141-146 (2004).
44. Ahmed AR, Tunis EJ, Khatri K et al.: Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl Acad. Sci. USA 87, 7658-7662 (1990).
45. Simmonds MJ, Gough SC: Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin. Exp. Immunol. 136(1), 1-10 (2004).
46. Ohsako N, Tamai H, Sudo T: Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J. Clin. Endocrinol. Metab. 80(12), 3653-3656 (1995).
47. Andreadis D, Laskaris G, Kapsokefalos P, Gagari E: Idiopathic Sweet's syndrome with oral manifestations. Case report and review of the literature. Acta Stomatol. Croat. 41(2), 152-158 (2007).
48. Magri F, Gabellieri E, Sorrentino AR, Rizza MI, Chiovato L, Ferrari E: Sweet's syndrome and thyroid diseases: is there a link. Endocrine Abstracts 11, P64 (2006
49. Tanaka K, Kajiyama. K, Imamaura T et al.: Genetic and environmental factors in the development of Behçet's Disease. Tohoku J. Exp. Med. 145(2), 205-213 (1985).
50. Kaya TI, Tursen U, Gurler A, Dur H: Association of class I HIA antigens with the clinical manifestations of Turkish patients with Behçet's disease. Clin. Exp. Dermatol. 27(6), 498-501 (2002).
51. Keskinbora HK, Mudin AB, Ayoglu I, Sonmez G, Carin M, Arslan MO: HLA antigenes in Behçet's Disease. J. Retina-Vitreous 3 (2), 170-176 (1995).
52. Flores-Villanueva PO, Hendel H, Caillat-Zucman S et al.: Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 170, 1925-1929 (2003).
53. Kato T, Kunikata N, Taira H, Kobayashi N, Tanji K, Endo M: Acute febrile neutrophilic dermatosis (Sweet's syndrome) with nodular episcleritis and polyneuropathy. Int. J. Dermatol. 41(2), 107-109 (2002).
54. Maat W, Haasnoot GW, Claas FHJ, Schalij-Delfos NE, Schreuder GMT, Jager Mj: HLA class I, II genotype in uveal melanoma: relation to occurrence and prognosis. Invest. Ophthalmol. Vis. Sci. 47(1), 3-6 (2006).
55. Gaya DR, Russell RK, Nimmo ER, Satsangi J: New genes in inflammatory bowel disease:lessons for complex diseases. Lancet 367, 1271-1284 (2006).
56. Brumme ZL, Brumme CJ, Chui C et al.: Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195(11), 1694-1704 (2007).
57. Acton RT, Go RCP, Roseman JM: Genetics and cardiovascular disease. Ethn. Dis. 14 (S2), 8-16 (2004).
58. Slomov E, Loewenthal R, Goldberg I, Korostishevsky M, Brenner S, Gazit E: Pemphigus vulgaris in Jewish patients is associated with HLA-A region genes: mapping by microsatellite markers. Hum. Immunol. 64(8), 771-779 (2003).
59. Gazit E, Loewenthal R: The immunogenetics ofpemphigus vulgaris. Autoimmun. Rev. 4(1), 16-20 (2005).
60. Song EY, Whang DH, Hur M, Kang SJ, Han KS, Park M H: HLA-B*44 allele frequencies and haplotypic associations in Koreans. Hum. Immunol, 63, 1142-1147 (2001).
61. DiBrino M, Parker KC, Margulies DH et al.: Identification of the pepticle binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biocbemistry 34, 10130-10138 (1995).
62. Mondino BJ, Brown SI, Biglan AW: HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch. Ophthalmol. 100, 1453-1454 (1982).
63. Cummings JR, Jewell DP: Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm. Bowel Dis. 11, 56-61 (2005).
64. Ozawa A, Sasao Y, Iwashita K et al.: HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). Tissue Antigens 53, 263-268. (1999).
65. Sato M, Ohashi J, Tsuchiya N et al.: Association of HLA-A*3303-B*4403-DRBI*1302 haplotype, but not of TNFA promoter and NKp3O polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun. 3, 477-481 (2002).
66. Jaber L, Weinberger A, Klein T, Yaniv I, Mukamel M: Close association of HLA-B52 and HLA-B44 antigens in Israeli Arab adolescents with recurrent aphthous, stomatitis. Arch. Otolaryngol. Head Neck Surg. 127(2),184-187 (2001).
67. Schrier RD, Freeman WR, Wiley CA, McCutchan JA, HNRC Group: Immune predispositions for cytomegalovirus retinitis in AIDS. J. Clin. Invest. 95, 1741-1746 (1995).
68. Li H, Dai Y, Huang H et al.: HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China. Environ. Health Perspect. 115(11), 1553-1556 (2007).
69. Kamijima M, Hisanagawa N, Wang H, Nakajima T: Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities. Int. Arch. Occup, Environ. Health 80, 357-370 (2007).
70. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118(2), 274-278 (2000).
71. Orchard TR, Dhar A, Simmons JD, Vaughan R, Welsh KI, Jewell DP: MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy. Clin. Exp. Immunol. 126(3), 437-440 (2001).
72. Grünhage F, Spengler U, Fischer HB, Sauerbruch T: Autoimmune hepatitis - sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion 70, 187-191 (2004).
73. Geisler WM, Tang J, Wang C, Wilson CM, Kaslow R.A: Epidemiological and genetic correlates of incident chlamydia trachomatis infection in North American adolescents. J. Infect. Dis. 190, 1723-1729 (2004).
74. Keet IPM, Klein MR, Just JJ, Kaslow RA: The role ofhost genetics in the natural history of HIV-1 infection: the needles in the haystack. AIDS 10(Suppl. A), S59-S67 (1996).
75. Flores-Villanueva PO, Yunis EJ, Delgado JC et al.: Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. PNAS 98(9), 5140-5145 (2001).
76. Kuzushita N, Hayashi N, Moribe T et al.: Influence of HLA haplotypes on the clinical course of individuals infected with hepatitis C virus. Hepatology 27, 240-244 (1998).
77. Price P, Keane NM, Stone SF, Cheong KY, French MA: MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum. Immunol. 62, 157-164 (2001).
78. Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood 99, 3844-3847 (2002).
79. Machulla HKG, Stein J, Gautsch A, Langner J, Schaller H-G, Reichert S: HLA-A, B, Cw, DRB1, DRB3/4/5, DQB1 in German patients suffering from rapidly progressive periodontitis (RPP) and adult periodontitis (AP). J. Clin. Periodontal. 29(6), 573-579 (2002).
80. Kotter I, Gunaydin I, Stubiger N et al.: Comparative analysis of the association of HLA-B*51 suballeles with Behçet's disease in patients of German and Turkish origin. Tissue Antigens 58, 166-170 (2001).
81. Gul A, Uyar FA, Inanc M et al.: Lack of association of HLA-B*5f with a severe disease course in Behçet's disease. Rheumatology 40, 668-672 (2001).
82. Horie Y, Namba K, Kitaichi N, Ohno S: Sister cases of Behçet's disease and Vogt-Koyanagi-Harada disease. Br. J. Ophthalmol. 92(3), 433-434 (2008).
83. Visser CJT, Tilanus MGJ, Tatari Z et al.: Sequencing-based typing of MICA reveals 33 alleles: a study on linkage with classical HLA genes. Immunogenetics 49, 561-566 (1999).
84. Ota M, Mizuki N, Katsuyama Y et al.: The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am. J. Hum. Genet. 64, 1406-1410 (1999).
85. Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K: Human leukocyte antigen in patients with Moyamoya disease. Stroke 26, 415-417 (1995).
86. Soto-Vega F, Garcia-Munoz R, Richaud-Patin Y et al.: Class I and class II MHC polymorphisms in Mexican patients with Behçet's disease. Immunol. Lett. 93, 211-215 (2004).
87. Ahmad T, Wallace GR, James T et al.: Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms. Arthritis Rheum. 48(3), 807-813 (2003).
88. Atasoy M, Pirim I, Bayrak OF et al.: Association of HLA class I and class II alleles with psoriasis vulgaris in Turkish population. Influence of type I, II psoriasis. Saudi Med. J. 27(3), 373-376 (2006).
89. Biral AC, Magalhaes RF, Wastowski IJ et al.: Association of HLA-A, -B, -C genes and TNF microsatellite polymorphism with psoriasis vulgafis: a study of genetic risk in Brazilian patients. Eur. J. Dermatol. 16(5), 523-529 (2006).
90. Stewart-Jones GB, Gillespie G, Overton IM et al.: Structures of three HIV-1 HLA-B*5703-peptide complexes and Identification of related HLAs potentially associated with long-term nonprogression. J. Immunol. 175, 2459-2468 (2005).
91. Fellay J, Shianna KV, Ge D et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944-947 (2007).
92. Brown J, Poles A, Brown CJ, Contreras M, Navarrete CV: HLA-A, -B and -DR antigen frequencies of the London Cord Blood Bank units differ from those found in established bone marrow donor registries. Bone Marrow Transplant. 25, 475-481 (2000).
93. Brown JH, Jardetzky TS, Gorga JC et al.: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33-39 (1993).
94. Chicz RM, Urban RG, Lane WS et al.: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogenous in size. Nature 358, 764-768 (1992).
95. O'Sullivan D, Arrhenius T, Sidney J et al.: On the interaction of promiscuous antigenic peptides with diferent DR alleles. J Immunol. 147, 2663-2669 (1991).
96. Martin AM, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19, 97-99 (2005).
97. MacDonald KS, Fowke KR, Kimani J et al.: Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect. Dis. 181, 1581-1589 (2000).
98. Ahmad T, Marshall SE, Jewell D: Genetics of inflammatory bowel disease: the role of the HLA complex. World J. Gastroenterol. 12(23), 3628-3635 (2006).
99. Moraes JR, Moraes ME, Fernandez-Vina M et al.: HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of Brazil. Immunogenetics 33, 388-391 (1991).
100. Pavoni DP, Roxo VM, Filho AM, Petzl-Erler ML: Dissecting the associations of endemic pemphigus foliaccus (fogo selvagem) with HLA-DRB1 alleles and genotypes. Genes Immun. 4, 110-116 (2003).
101. Scharf SJ, Freidmann A, Steinman L, Brautbar C, Erlich HA: Specific HLA-DQB and HLA-DRBJ alleles confer susceptibility to pemphigus vulgaris. Proc. Natl Acad. Sci. USA 86, 6215-6219 (1989).
102. Scharf SJ, Long CM, Erlich HA: Sequence analysis of the HLA-DRβ and HLA-DQβ loci from three pemphigus vulgaris patients. Hum. Immunol. 22, 61-69 (1988).
103. Altmann DM: HLA-DQ associations with auto-immune disease. Autoimmunity 14, 79-83 (1992).
104. Anaya JM, Gómez L, Castiblanco J: Is there a common genetic basis for autoimmune diseases. Clin. Dev. Immunol. 13(2-4), 185-195 (2006).
105. Alpsoy E, Yilmaz E, Coskun M, Savas A, Yegin O: HLA antigens and linkage disequilibrium patterns in Turkish Behçet's patients. J Dermatol. 25, 158-162 (1998).
106. Sun A, Lin SC, Chu CT, Chia0ng CP: HLA-DR and DQ antigens in Chinese patients with Behçet's disease. J Oral Pathol. Med. 22 (2), 60-63 (1993).
107. Fain PR, Babu SR, Bennett DC, Spritz RA: HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res. 19, 51-57 (2005).
108. Pirim I, Atasoy M, Ikbal M, Erdem T, Aliagaoglu C: HLA class I and class II genotyping in patients with Behçet's disease: a regional study of eastern part of Turkey. Tissue Antigens 64(3), 293-297 (2004).
109. Britschgi M, Steiner UC, Schmid S et al.: T-cell involvement in dfug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. 107, 1433-1441 (2001).
110. Stein J, Reichert S, Gautsch A, Machulla HK: Are there HLA combinations typical supporting for or making resistant against aggressive and/or chronic periodontitis. J. Periodontal Res. 38(5), 508-517 (2003).
111. Sun A, Hsieh RP, Chu CT, Wang JT, Liu BY, Chiang CP: Some specific HLA DR/DQ haplotypes are more important than individual HLA-DR and -DQ phenotypes for development of mucocutaneous type of Behçet's disease and for disease shiftfrom recurrent aphthous stomatitis to mucocutaneous type of Behçet's disease. J. Oral Pathol. Med. 30, 402-407 (2001).
112. Lombardini ML, Mercuro O, Ruocco V et al.: Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J. Invest. Dermatol. 113(1), 107-110 (1999).
113. Gladman DD, Farewell VT, Rahman P et al.: HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. Hum. Immunol. 62, 1239-1244 (2001).
114. de Bruin A, Moller E, Parisi S et al.: Antigenic targets of autoantibodies in canine paraneoplastic pemphigus. J. Dermatol. Sci. 16(1), S38 (1998).
115. Martel P, Loiseau P, Joly P et al.: Paraneoplastic pemphigus is associated with the DRB1*03 allele. J. Autoimmun. 20(1), 91-95 (2003).
116. Baumgart DC, Buning C, Geerdts L et al.: The c.1-260C1 T promoter variant of CD14 but not the c.896A 1 G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 76, 196-202 (2007).
117. Wiencke K, Karlsen TH, Boberg KM et al.: Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes Tissue Antigens 69(2), 161-169 (2007).
118. Foilack MS, Gold J, Metroka CE, Safai B, Dupont B: HLA-A, B, C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections. Hum. Immunol. 11(2), 99-103 (1984).
119. Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ: HLA antigen frequencies in HIV-1-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. 3(Suppl. 1), S51-S55 (1990).
120. Taylor C, Smith S, Morgan C et al.: HLA and Mooren's ulceration. Br. J. Qphthalmol. 84(1), 72-75 (2000).
121. Weinshenker B, Santrach P, Bissonet A et al.: Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51(3), 742-747 (1998).
122. Rataziachaiyavong S, Lloyd L, Darke C, McGregor A: MHC-extended haplotypes in families of patients with Graves' disease. Hum. Immunol. 36(2), 99-111 (1993).
123. Tjernstrom F. Hellmer G, Nived O, Truedsson L, Sturfelt G: Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17, DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 8(2), 103-108 (1999).
124. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J: HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 156(5), 1601-1605 (1997).
125. Planck A, Katchar K, Eklund A, Gripenbäck S, Grunewald J: T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vase. Diffuse Lung Dis. 20 (2), 110-117 (2003).
126. Suastegui R, De La Rosa G, Carranza J, Gonzalez-Astiazaran A, Gorodezky C: Contribution of the MHC class II antigens to the etiology of infantile spasm in Mexican. Mestizos. Epilepsia 42(2), 210-215 (2001).
127. Piyasirisilp S, Schmeckpeper B, Chandanayingyong D, Hemachudha T, Griffin D: Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann. Neurol. 45(5). 595-600 (1999).
128. Diamantopoulos E, Andreadis E, Vassilopoulos C et al.: Association of specific HLA phenotypes with left ventricular mass and carotid intima-media thickness in hypertensives. Am. J. Hypertens. 14(7 Pt 1), 632-636 (2001).
129. Yang J, Qiao HL, Zhang YW, Jia LJ, Tian X, Gao N: HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins. Chin. Med. J. 119(6), 458-466 (2006).
130. Dieye A, Diallo S, Diatta M et al.: Identification of HLA-DR alleles for susceptibility to rheumatoid polyarthritis in Senegal. Dakar Med. 42(2), 111-113 (1997).
131. Talal N: Sjogren's syndrome Curr. Opin. Immunol. 2, 622-624 (1990).
132. Gorski J, Rollini P, Mach B: Structural comparison of the genes of two HLA-DR supertypic groups: the loci encoding DRw52 and DRw53 are not truly allelic. Immunogenetics 25 (6), 397-402 (1987).
133. Iannuzzi MC, Rybick BA: Genetics of sarcoidosis. Candidate genes and genome.scans. Proc. Am. Thorac Soc. 4, 108-116 (2007).
134. Ferrer CP, Vial CPA, Ferrés GM et al.: Genetic susceptibility to Andes Hantavirus: association between severity of disease and HLA alleles in Chilean patients. Rev. Chil. Infect. 24(5), 351-359 (2007).
135. Vani S, Pitchappan RM: Host genetics and infectious diseases in South India. Int. J. Hum. Genet. 6(1), 41-48 (2006).
136. Oksenberg JR, Barcellos LF, Cree BA et al.: Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet. 74, 160-167 (2004).
137. Sospedra M, Muraro P, Stefanova I et al.: Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 hoplotype. J. Immunol. 176(3), 1951-1961 (2006).
138. Joko S, Numaga J, Kawashima H, Namisato M, Maeda H: Human leukocyte antigens in forms of leprosy among Japanese patients. Int. J. Lepr. Other Mycobact. Dis. 68(1), 49-56 (2000).
139. Vogt AB, Kropshofer H, Kalbachcr H et al.: Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153, 1665-1673 (1994).
140. Gregersen JW, Kranc KR, Ke X et al.: Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443, 574-577 (2006).
141. Zamani M, Spaepen M, Sghar S et al.: Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br. J. Dermatol. 145(1), 90-94 (2001).
142. Corzo D, Yunis J, Salazar M et al.: The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86(10), 3835-3840 (1995).
143. Kobayashi H, Kokubo T, Takahashi M et al.: Tyrosinase epitope recognized by an HLA-DR-restricted T-cell fine from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 47(5), 398-403 (1998).
144. Morita Y, Moriuchi J, Inoko H, Tsuji K, Arimori S: HLA class II antigens and DNA restriction fragment length polymorphism in myasthenia gravis in Japan. Ann. Neurol. 29(2), 168-174 (1991).
145. Shimoda S, Nakamura M, Ishibashi H, Hayashida Y, Niho Y: HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J. Exp. Med. 181(5), 1835-1845 (1995).
146. Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16, 457-499 (1998).
147. Dinarello CA: Blocking IL-1 in systemic inflammation. J. Exp, Med. 201(9), 1355-1359 (2005).
148. Cremona S, Goujon E, Kelley KW, Dantzer R, Parnet P: Brain type I but not type II IL-1 receptors mediate the effects of IL-1β on behaviour in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 274, R735-R740 (1998).
149. Sims JE, Gayle MA, Slack JL et al.: Interleukin 1 signaling occurs exclusively via the type receptor I. Proc. Natl Acad. Sci. USA 90, 6155-6159 (1993).
150. Colotta F, Re F, Muzio M et al.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261(5120), 472-475 (1993).
151. Cototta, F, Dower SK, Sims JE, Mantovani, A: The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol. Today 15, 562-566 (1994).
152. Ueta M, Sotozono C, Inatomi T, Kojima Y, Hamuro J, Kinoshita S: Association of IL4R polymorphisms with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 120(6), 1457-1459 (2007).
153. Muller B, Peri G, Doni A et al.: High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J. Leukoc Biol. 72, 643-649 (2002).
154. Cubitt CL, Lausch RN, Oakes JE: Synthesis of type II interleukin-1 receptors by human corneal epithelial cells but not by keratinocytes. Invest. Opthalmol. Vis. Sci. 42, 701-704 (2001).
155. Nishimura T, Abe H, Ito H, Ikeda K, Oka F, Yamamoto M: IL-1RA versus IL-1 levels in prostatic fluid from prostatitis patients. Urol. Int. 60(2), 92-96 (1998).
156. Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y: Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18(2), 399-407 (2006).
157. Elkon KB: IL-1α responds to necrotic cell death. Nat. Med. 13, 778-780 (2007).
158. Vogels MT, Eling WM, Otten A, van der Meer JW: Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type 1 IL-1 receptor. Antimicrob. Agents Chemother. 8, 1744-1747 (1995).
159. McGarry F, Neilly J, Anderson N, Sturrock R, Field MA: Polymorphism within the interleukin 1 receptor antagonist (IL-1RA) gene is asscoiated with ankylosing spondylitis. Rheumatology 40, 1359-1364 (2001).
160. Horai R, Saijo S, Tanioka H et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320 (2000).
161. Prince LR, Allen L, Jones EC et al.: The role of interleukin-1β in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am. J. Pathol. 165(5), 1819-1826 (2004).
162. Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A: Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. Rheumatology 42, 860-864 (2003).
163. Ferrari D, Pizzirani C, Adinolfi E et al.: The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176, 3877-3883 (2006).
164. Fichorova RN, Bajpai M, Chandra N et al.: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 71, 761-769 (2004).
165. Glasgow SC, Ramachandran S, Blackwell TS, Mohanakumar T, Chapman WC: Interleukin-1β is the primary initiator of pulmonary inflammation following liver injury in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L491-L496 (2007).
166. Horai R, Asano M, Sudo K et al.: Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β and IL-1 receptor antagaonist shows that IL-1β is crucial in turpentime-induced fever develoment and glucocorticoid secretion. J. Exp. Med. 187, 1463-1475 (1998).
167. van Minkelen R, de Visser MCH, Houwing-Duistermaat JJ et al.: Haplotypes of ILIB, IL1RN, IL1R1 and IL1R2 and the risk of venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 1486-1491 (2007).
168. Juge-Aubry CE, Somm E, Chicheportiche R et al.: Regulatory effects of interleukin (IL)-1, interferon-β, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J. Clin. Endocrinal. Metab. 89(6), 2652-2658 (2004).
169. Park JW, Taube C, Swasey C et al.: Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness during exposure to ozone. Am. J Respir. Cell Mol. Biol. 30, 830-836 (2004).
170. Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C: Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. J. Leukoc. Biol. 75, 738-742 (2004).
171. Hultgren OH, Svensson L, Tarkowski A: Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J. Immunol. 168, 5207-5212 (2002).
172. Gourine AV, Leon LR, Rudolph K, Korsak AS, Kluger J: Anterior hypothalamic interleukin-1 receptors are involved in mediation of fever during bacterial sepsis in rats. Ann. NY Acad. Sci. 856, 266-269 (1998).
173. Chou CT, Timms AE, Wei JCC, Tsai WC, Wordsworth BP, Brown MA: Replication of association of IL-1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann. Rheum. Dis. 65, 1106-1109 (2006).
174. Akira S, Takeda Y, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680 (2001).
175. O'Neill LAJ, Greene C: Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc. Biol. 63, 650-657 (1998).
176. Cateni C, Paulesu L, Bigliardi E, Hamlett WC: The interleukin 1 (IL-1) system in the uteroplacental complex of a cartilaginous fish, the smoothhound shark, Mustellus canis. Reprod. Biol. Endocrinol. 1, 25 (2003).
177. Akoum A, Jolicoeur C, Kharfi A, Aube M: Decreased expression of the decoy interleukin-1 receptor type II in human endometriosis. Am. J Pathol. 158, 481-489 (2001).
178. Bellehumeur C, Collette T, Maheux R, Mailloux J, Villeneuve M, Akoum A:
179. Kharfi A, Boucher A, Akouni A: Abnormal interleukin-I receptor type II gene expression in the endometrium of women with endometriosis. Biol. Reprod. 66, 401-406 (2002).
180. Fredericks Z, Forte C, Capuano I, Zhou H, Vanden Bos T, Carter P: Identification of potent human anti-IL-IR1 antagonist antibodies. Protein Eng. Des. Sel. 17, 95-106 (2004).
181. Lang D, Knop J, Wesche H et al.: The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J. Immunol. 161, 6871-6877 (1998).
182. Bigonnesse F, Marois M, Malheux R, Akoum A: Interleukin-1 receptor accessory protein is constituently expressed in human endometrium throughout the menstrual cycle. Mol. Hum. Reprod. 7, 333-339 (2001).
183. Liu JSH, Amaral TD, Brosnan CF, Lee SC: IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J. Immunol. 161, 1989-1996 (1998).
184. Biedermann T, Kneilling M, Mailhammer R et al.: Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192(10), 1441-1451 (2000).
185. Martin A, Nolan D, Altneida CA, Rauch A, Mallal S: Predicting and diagnosing abacavir and nevirapine drug hypersensivity: from bedside to bench and back again. Pharmacogenomics 7(1), 15-23 (2006).
186. Bellamy R: Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun. 4, 4-11 (2003).
187. Pascual V, Farkas L, Banchereau J: Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 18, 676-682 (2006).
188. + T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J. Immunol. 155, 452-472 (1995).
189. Martin AM, Nolan D, Gaudieri S et al.: Predisposition to abacavir hypersensitivity confered by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004).
190. Kouki T, Gardine CA, Yanagawa T, Degroot LJ: Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J. Endocrinol. Invest. 25(3), 208-213 (2002).
191. Kristiansen OP. Larsen ZM, Pociot FC: TLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity. Genes Immun. 1, 170-184 (2000).
192. Simpson E: Special regulatory T-cell review: regulation of immune responses - examining the role of T cells. Immunology 123, 13-16 (2007).
193. Munthe-Kaas MC, Carlsen KH, Helms PJ et al.: CTLA-4 polymorphisms in allergy and asthma and the Th1/Th2 paradigm. J. Allergy Clin. Immunol. 114(2), 280-287 (2004).
194. Vaidya B, Pearce S: The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur. J. Endocrinol. 150(5), 619-626 (2004).
195. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA, Gough SC: Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid 12(1), 3-6 (2002).
196. King AL, Moodie SJ, Fraser JS et al.: Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur. J. Immunogenet. 30(6), 427-432 (2003).
197. Tomer Y, Davies TF: Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev. 24(5), 694-717 (2003).
198. Terauchi M, Yanagawa T, Ishikawa N et al.: Interactions of HLA-DRB4 and CTLA-4 genes influence thyroid function in Hashimoto's thyroiditis in Japanese population. J. Endocrinol. Invest. 26 (12), 1208-1212 (2003).
199. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A et al.: The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of Type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur. J. Hum. Genet. 11(1), 81-84 (2003).
200. Alizadeh M, Babron MC, Birebent B et al.: Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. Ann. Neurol. 54(1), 119-122 (2003).
201. Ueta M, Sotozono C, Inatomi T, Tashiro K, Hamuro J, Kinoshita S: Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens - Johnson syndrome. Br. J. Ophthalmol. 91, 962-965 (2007).
202. Raz E: Organ-specific regualtion of innate immunity. Nat. Immunol. 8(1), 3-4 (2007).
203. Matsumura Y, Hayashi H, Taikii T et al.: TGF-β down-regulates IL-α-induced TLR2 expression in murine hepatocytes. J. Leukoc. Biol. 75, 1056-1061 (2004).
204. Pan P-Y, Rothman P: IL-4 receptor mutations. Curr. Opin. Immunol. 11, 615-620 (1999).
205. Yamada A, Kimura S: Induction of uteroglobin-related protein2 (Ugrp2) expression by EGF, TGFα. FEBS Lett. 579(10), 2221-2225 (2005).
206. Saleem S, Dai Z, Coelho SN et al.: IL-4 is an endogenous inhibitor of neutrophil influx and subsequent pathology in acute antibody-mediated inflammation. J. Immunol. 160, 979-984 (1998).
207. Crepaldi L, Silveri L, Calzetti F, Pinardi C, Casatella MA: Molecular basis of the synergistic prodcution of IL-1 receptor antagonist by human neutrophils stimulated with IL-4 and IL-10. Int. Immunol. 14, 1145-1153 (2002).
208. Sambrook JG, Beck S: Evolutionary vignettes of narural killer cell receptors. Curr. Opin. Immunol. 19, 553-560 (2007).
209. Trapani JA, Davis J, Sutton VR, Smyth MJ: Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr. Opin. Immunol. 12(3), 323-329 (2000).
210. Catalfamo M, Henkart PA: Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol. 15(5), 522-527 (2003).
211. Moretta L, Moretta A, Hengartner H, Zinkernagel RM: On the pathogenesis of perforin defects and related immunodeficiencies. Immunol. Today 21(11), 593-594 (2000).
212. Stepp S, Mathew P, Bennett M, de Saint Basile G, Kumar V: Response to Moretta et al. and Arnaout. Immunol. Today 21(11), 593-594 (2000).
213. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ: Apoptosis induced by the lymphocyte effector molecule perforin. Curr. Opin. Immunol. 19(3), 339-347 (2007).
214. Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V: Perforin: more than just an effector molecule. Immunol. Today 21(6), 254-256 (2000).
215. Krauss G: Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 6(2), 33-37 (2006).
216. Naisbitt DJ, Britschgi M, Wong G et al.: Hypersensitivity reactions to carbamazepine: characterisation of the specificity, phenotype, and cytokine profile of drug specific T cell clones. Mol. Pharmacol. 63, 732-741 (2003).
217. Hernandez-Pigeon H, Jean C, Charruyer A et al.: Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. implication of granzyme B and perforin. J. Biol. Chem. 281(19), 13525-13532 (2006).
218. Schmid S, Kuechler PC, Britschgi M et al.: Acute generalized exanthematous pustulosis. role of cytotoxic T cells in pustule formation. Am. J. Pathol. 161(6), 2079-2086 (2002).
219. French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: Our current understanding. Allergol. Int. 55, 9-16 (2006).
220. Viard I, Wehrli P, Bullani R et al.: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
221. Feng ML, Guo XJ, Zhang JY et al.: Study on the haplotypes of MICA and MICB microsatellite and HLA-8 locus in the Guangzhou Han population. Tissue Antigens 64(3), 281-285 (2004).
222. Tian W, Boggs DA, Uko G et al.: MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes Immun. 4(7), 500-505 (2003).
223. Martinez A, Fernandez-Arquero M, Balsa A et al.: Primary association of a MICA allele with protection against rheumatoid arthritis. Arthritis Rheum. 44(6), 1261-1265 (2001).
224. Goto K, Ota M, Ando H et al.: MICA gene polymorphisms and HLA-B27-subtypes in Japanese patients with HIA-B27-associated acute anterior uveitis. Invest. Ophthalmol. Vis. Sci. 39, 634-637 (1998).
225. Mizuki N, Ota M, Kimura M et al.: Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc. Natl Acad. Sci. USA 94, 1298-1303 (1997).
226. Verity DH, Wallace GR, Vaughan RW, Stanford MR: Behçet's disease: from Hippocrates to the third millennium. Br. J. Ophthalmol. 87, 1175-1183 (2003).
227. Gardiner CM: Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int. J. Immunogenet. 35, 1-8 (2007).
228. Scott I, O'Shea J, Bunce M et al.: Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/ patient pairs: implications for unrelated bone marrow donor selection. Blood 92(12), 4864-4871 (1998).
229. Bishara A, Amar A, Brautbar C, Condiotti R, Lazarovitz V, Nagler A: The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT). Exp. Hematol. 23, 1667-1675 (1995).
230. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A: Human natural killer cells: origin, clonality specificity, and receptors. Adv. Immunol. 55, 341-380 (1994).
231. Petersdorf EW, Longton GM, Anasetti C et al.: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89, 1818-1823 (1997).
232. Allcock RJN, Williams JH, Price P: The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production. Genes Cells 6, 487-494 (2001).
233. Randolph AG, Lange C, Silverman EK, Lazarus R, Weiss ST: Extended haplotype in the tumor necrosis factor gene cluster is associated with asthma and asthma-related phenotypes. Am. J. Respir. Crit. Care Med. 172, 687-692 (2005).
234. Tumanov AV, Christiansen PA, Fu YX: The role of lymphotoxin receptor signaling in diseases. Curr. Mol. Med. 7, 567-578 (2007).
235. Kollias G, Douni E, Kassiotis G, Kontoyiannis D: The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann. Rheum. Dis. 58(Suppl. I), I32-I39 (1999).
236. Westendorp RGJ, van Dunne FM, Kirkwood TB, Helmerhorst FM, Huizinga TW: Optimizing human fertility and survival. Nat. Med. 7(8), 873 (2001).
237. Yang IA, Holz O, Jorres RA et al.: Association of tumor necrosis factor-α polymorphisms and ozone-induced change in lung function. Am. J. Respir. Crit. Care Med. 171(2), 171-176 (2005).
238. Hirankarn N, Avihingsanon Y, Wongpiyabovorn J: Genetic susceptibility to SLE is associated with TNF-α gene polymorphism -863, but not -308 and -238, in Thai population. Int. J. Immunogenet. 34, 425-430 (2007).
239. Verity DH, Wallace GR, Vaughan RW et al.: HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease. Tissue Antigens 54(3), 264-272 (1999).
240. Park K, Kim N, Nam J, Bang D, Lee ES: Association of TNFA promoter region haplotype in Behçet's disease. J. Korean Med. Sci. 21, 596-601 (2006).
241. Labunski S, Posern G, Ludwig S, Kundt G, Brcker EB, Kunz M: Tumour necrosis factor-α promoter polymorphism in erythema nodosum. Acta Derm. Venereol. 81(1), 18-21 (2001).
242. Church LD, Cook GP, McDermott MF: Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat. Clin. Pract. Rheumatol. 4(1), 34-42 (2008).
243. Hoffman HM, Rosengren S, Boyle DL et al.: Prevention of cold-associated acute inflammation in familial cold auto-inflammatory sysndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004).
244. Wanderer AA, Hoffman HM: The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol. Allergy Clin. North Am. 24(2), 259-286 (2004).
245. Touitou I, Lesage S, McDermott M et al.: Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum. Mutat. 24, 194-198 (2004).
246. Stankovic K, Grateau G: Auto inflammatory syndromes: diagnosis and treatment. Joint Bone Spine 74(6), 544-550 (2007).
247. Church LD, Churchman SM, Hawkins PN, McDermott MF: Hereditary autoinflammatory disorders and biologics. Springer Semin. Immunopathol. 27(4), 494-508 (2006).
248. Ozen S: Familial mediterranean fever: revisiting an ancient disease. Eur. J. Pediatr. 162(7-8), 449-454 (2003).
249. Bletsa A, Heyeraas KJ, Haug SR, Berggreen E: IL-1α and TNF-α expression in rat peripacial lesions and dental pulp after unilateral sympathectomy. Neuroimmunomodulation 11, 376-384 (2004).
250. Bletsa A, Heyeraas KJ, Berggreen E: Edema in oral mucosa after LPS or cytokine exposure. J. Dent. Res. 85(5), 442-446 (2006).
251. Brito BE, O'Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT: IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex of uveitis. Invest. Opthalmol. Vis. Sci. 40, 2583-2589 (1999).
252. Shipall RL, Jeffes EWB, Hoffman HM: A case of familial cold auto-inflammatory syndrome confirmed by the presence of a CIAS1 mutation. Br. J. Dermatol. 150, 1028-1054 (2004).
253. Touitou I, Perez C, Dumont B, Federici L, Jorgensen C: Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations. Ann. Rheum. Dis. 65, 1530-1531 (2006).
254. Zelano G, Settesoldi D, Lino MM, Batocchi A, Evoli A, Tonali PA: Thymic disorders and myasthenia gravis: genetic aspects. Ann. Med. 31(Suppl. 2), 46-51 (1999).
255. Soto-Vega E, Richaud-Patin Y, Llorente L: Human leukocyte antigen class I, class II, and tumor necrosis factor-α polymorphisms in a healthy elder Mexican Mestizo population. Immun. Ageing 2, 13 (2005).
256. Lehner T: The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int. Rev. Immunol. 14, 21-32 (1997).
257. Yamakawa Y, Sugita Y, Takahashi Y et al.: Gene expression of tumour necrosis factor- (TNF) and heat-shock protein (HSP) 70 in patients with Behȩt's disease. Arch. Dermatol. Res. 285, 505-508 (1993).
258. Warren LL, Hughes AR, Lai EH et al.: Use of pair-wise marker combinations and recursive partitioning in a pharmacogenetic genome-wide scan. Pharmacogenomics J. 1-10 (2006).
259. Vaux DL, Flavell RA: Apoptosis genes and autoimmunity. Curr. Opin. Immunol. 12(6), 719-724 (2000).
260. Namjou B, Kilpatrick J, Harley JB: Genetics of clinical expression in SLE. Autoimmunity 40(8), 602-612 (2007).
261. Morling N, Andersen V, Fugger L et al.: Immunogenetics of rheumatoid arthritis and primary Sjogren's syndrome: DNA polymorphism of HLA class II genes. Dis. Markers 9(5), 289-296 (1991).
262. Kobayashi K, Atoh M, Yagita A et al.: Crohn's disease in the Japanese is associated with the HLA-DRw3. Exp. Clin. Immunogenet. 7(2), 101-108 (1990).
263. Chen Q, Huang W, She J, Baxter F, Volpe R, Maclaren N: HLA-DRB1*08, DRB1*031 DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J. Clin. Endocrinol. Metab. 84(9), 3182-3186 (1999).
264. Isenberg D, Maddison P, Woo P, Glass D, Breedveld F: Oxford Textbook of Rheumatology. Oxford University Press, Oxford, UK 1304 (2004).
265. Jankowski J, Crombie I, Jankowski R: Behçet's syndrome in Scotland. Postgrad. Med. J. 68, 566-570 (1992).
266. O'Duffy JD, Kokmen E, O'Duffy J: Behçet's Disease: Basic and Clinical Aspects. Informa Health Care, London, UK 696 (1991).
267. Hirohata S, Kikuchi H: Behoçet's disease. Arthritis Res. Ther. 5, 139-146 (2003).
268. Sharquie KE, Najim RA, Al-Janabi MH: HLA antigen, severity and acetylator phenotype in Bchçet's disease patients with non-relative parents. In: Adamantiades-Behçet's Direase. Zouboulis CC (Ed.). Springer, Berlin, Germany 655 (2003).
269. Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH: HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea. Clin. Exp. Rheumatol. 19 (5 Suppl. 24), S31-S35 (2001).
270. Kilmartin DJ, Finch A, Acheson RW: Primary association of HLA-B51 with Behçet's disease in Ireland. Br. J. Ophthalmol. 81, 649-653 (1997).
271. Hno S, Ohgami M, Hirose S, Matsuda H, Wakisaka A, Aizawa M: Close association of HLA-Bw51 with Behçet's disease. Arch. Ophthalmol. 100(9), 1455-1458 (1982).
272. Choukri F, Chakib A, Himmich H, Marih L, Caillat-Zucman S: HLA-B phenotype modifies the course of Behçet's disease in Moroccan patients. Tissue Antigens 61(1), 92-96 (2003).
273. Arber N, Klein T, Meiner Z, Pras E, Weinberger A: Close association of HLA-B51 and B52 in Israeli patients with Behçet's syndrome. Ann. Rheum. Dis. 50, 351-353 (1991).
274. Zeis J: Essential Guide to Beçet's Disease. Central Vision Press, MA, USA 198 (2003).
275. Schrier RW: Diseases of the Kidney Urinary Tract. Lippincott Williams & Wilkins, PA, USA 3776 (2007).
276. Mizuki N, Ohno S, Ando H et al.: HLA-C genotyping of patients with Behçet's disease in the Japanese population. Hum. Immunol. 50(1), 47-53 (1996).
277. Cohen R, Metzger S, Nahir M, Chajek-Shaul T: Association of the MIC-A gene and HLA-B51 with Behçet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann. Rheum. Dis. 61, 157-160 (2002).
278. Mizuki N, Inoko H, Ohno S: Molecular genetics (HLA) of Behçet's disease. Yonsei Med. J. 38(6), 333-349 (1997).
279. Yabuki K, Mizuki N, Ota M et al.: Association of MICA gene and HLA-B*5101 with Behçet's disease in Greece. Invest. Ophthalmol. Vis. Sci. 40, 1921-1926 (1999).
280. Zierhut M, Shigeaki O: Immunology of Behçet's Disease. Taylor Francis, Oxford, UK 188 (2003).
281. Triolo G, Accardo-Palumbo A, Dieli F et al.: Humoral and cell mediated immune response to cow's milk proteins in Behçet's disease. Ann. Rheum. Dis. 61(5), 459-462 (2002).
282. Sun A, Chang JG, Kao CL et al.: Human cytomegalovirus as a potential etiologic agent in recurrent aphthous ulcers and Behçet's disease. J. Oral Pathol. Med. 25 (5), 212-218 (1996).
283. Sohn S, Lee ES, Bang D, Lee S: Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur. J. Dermatol. 8, 21-23 (1998).
284. Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int. J. Dermatol. 42(10), 761-778 (2003).
285. von den Driesch P: Sweet's syndrome (acute febrile neutrophilic dermatosis). J. Am. Acad. Dermatol. 31(4), 535-556 (1994).
286. Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T-cell type 1 cytokines. J. Am. Acad. Dermatol. 39, 940-943 (1998).
287. Barnhill RL, Busam KJ: Vascular diseases. In: Histopathology of the Skin. Elder D (Ed.)., Lippincott-Raven, NY, USA 204-206 (1997).
288. Jeanfils S, Joly P, Young P et al.: Indomethacin treatment of eighteen patients with Sweet's syndrome. J. Am. Acad. Dermatol. 36, 436-439 (1997).
289. Reussborst MA, Pawelec G, Saal JG et al.: Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br. J. Hematol. 84, 356-358 (1993).
290. von den Driesch P, Grushwitz M, Hornstein OP et al.: Adhesion molecule modulation in Sweet's syndrome compared with erythema multiforme. Eur. J. Dermatol. 3, 393-397 (1993).
291. Mizoguchi M, Matsuki M, Mochizuki M et al.: Human leukocyte antigen in Sweet's syndrome and its relationship to Behçet's syndrome. Arch. Dermatol. 124, 1069-1073 (1988).
292. von den Driesch P, Simon M, Djawari D et al.: Analysis of HLA antigens in Caucasian patients with acute febrile neutrophilic dermatosis (Sweet's syndrome). J. Am. Acad. Dermatol. 37, 276-278 (1997).
293. Walker DC, Cohen PR: Trimethoprim- sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J. Am. Acad. Dermatol. 34(5 Pt 2), 918-923 (1996).
294. Gilmour E, Chalmers RJG, Rowlands DJ: Drug-induced Sweet's syndome (acute febrile neutrophilic dermatosis) associated with hydralazine. Br. J. Dermatol. 133, 490-491 (1995).
295. Satra D, Zalka A, Cohen PR et al.: Sweet's syndrome and pregnancy. J. Am. Acad. Dermatol. 30(2 Pt 2), 297-300 (1994).
296. Hisanaga K, Hosokawa M, Sato N, Mochizuki H, Itoyama Y, Iwasaki Y. 'Neuro-sweet disease': benign recurrent encephalitis with neutrophilic dermatosis. Arch. Neurol. 56(8), 1010-1013 (1999).
297. Kaori I, Kentaro D, Hisashi N et al.: A case of neuro-Behçet's disease with HLA B54 and predominant cerebral white matter lesions. Clin. Neurol. 40(9), 921-925 (2000).
298. Takenao C, Tadashi N, Reiko K: Sweet syndrome with Sjoegren syndrome. Hifuka No Rinsho 46(7), 1037-1040 (2004).
299. Correia O, Delgado L, Roujeau JC, le Cleach L, Fleming-Torrinha JA: Soluble interleukin 2 receptor and interleukin 1α in toxic epidermal necrolysis. A comparative analysis of serum and blister fluid samples. Arch. Dermatol. 138, 29-32 (2002).
300. Toje M, Zheng X, Yanagihori H et al.: Detection of herpes virus genomes in skin lesions from patients with Behçet's disease and other related inflammatory diseases. Acta Derm. Venereol. 83, 124-127 (2003).
301. Lee MS, Barnetson R St C: Sweet's syndrome associated with Behçet's disease. Australas. J. Dermatol. 37(2), 99-101 (1996).
302. Ciompi ML, Marchetti G, Bazzichi L, Puccetti L, Agelli M: D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Rheumatol. Int. 15, 95-97 (1995).
303. Tron F, Gilbert D, Mouquet H et al.: Genetic factors in pemphigus. J. Autoimmun. 24(4), 319-328 (2005).
304. Davies TF: Autoimmune thyroid disease genes come in many styles and colors. J. Clin. Endocrinol. Metab. 83(10), 3391-3393 (1998).
305. Meth MJ, Sperber KE: Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. Mt Sinai J. Med. 73(5), 769-776 (2006).
306. Heimer H: Outer causes inner conflicts: environment and autoimmunity. Environ. Health Perspect. 107(10), A504-A509 (1999).
307. Horton R, Gibson R, Coggill P et al.: Variation analysis and gene annotation of eight MHC haplotypes: The MHC Haplotype Project. Immunogenetics 60, 1-18 (2008).
308. Dorak MT, Shao W, Machulla HK et al.: Conserved extended haplotypes of the major histocompatibility complex: further characterization. Genes Immun. 7, 450-467 (2006).
309. Lehner T, Welsh KI, Batchelor JR: The relationship of HLA-B and DR phenotypes to Behçet's syndrome, recurrent oral ulceration and the class of immune complexes. Immunology 47(4), 581-587 (1982).
310. Lehner T, Batchelor JR: Classification and in immunogenetic basis of Behçet's syndrome. In: Behçet's Syndrome. Lehner T, Barnes CG (Eds). Academic Press, London, UK 13 (1979).
311. + T cells provides the immunogentic basis for systemic drug hypersensivity. Immunity 28, 822-832 (2008).
312. Lopez-Vazquez A, Mina-Blanco A, Martinez- Borra J et al.: Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum. Immunol. 66, 285-289 (2005).
313. Martin MP, Qi Y, Gao X et al.: Innate partnership of HIA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39(6), 733-740 (2007).
314. Hung S, Chung W, Liou L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
315. Hung S, Chung W, Jee S et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacegenet. Genomics 16(4), 297-306 (2006).
316. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
317. Cooper GS, Miller FW, Pandey JP: The role of genetic factors in autoimmune disease: implications for environmental research. Environ. Health Perspect. 107(Suppl. 5), 693-700 (1999).
318. Shlomovitz E, Davies W, Cairns W, Brintnell WC, Goldszmidt M, Dresser GK: Severe necrotizing pancreatitis following combined hepatitis A and B vaccination. CMAJ 176(3), 339-342 (2007).
319. Jorde LB, Wooding SP: Genetic variation, classification and 'race'. Nat. Genet. 36(Suppl. 11), S28-S33 (2004).
320. Baranzini SE: Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis. Autoimmunity 39(8), 651-662 (2006).
321. Sharp AJ, Cheng Z, Eichler EE: Structural variation of the human genome. Annu. Rev. Genomics Hum. Genet. 7, 407-442 (2006).
322. Dunn DS, Choy MK, Phipps ME, Kulski JK: The distribution of major histocompatibility complex class I polymorphic Alu insertions and their associations with HLA alleles in a Chinese population from Malaysia. Tissue Antigens 70, 136-143 (2007).
323. Dunn DS, Romphruk AV, Leelayuwat C, Bellgard M, Kulski JK: Polymorphic Alu insertions and their associations with MHC class I alleles and haplotypes in the Northeastern Thais. Ann. Hum. Genet. 69, 364-372 (2005).
324. Dunn DS, Tait BD, Kulski JK: The distribution of polymorphic Alu insertions within the MHC class I HLA-B7 and HLA-B57 haplotypes. Immunogenetics 56, 765-768 (2005).
325. Ray DA: SINEs of progress: mobile element applications to molecular ecology. Mol. Ecol. 16, 19-33 (2007).
326. Muller-Hilke B, Michison NA: The role of HLA promoters in autoimmunity. Curr. Pharm. Des. 12, 3743-3752 (2006).
327. Shaffer AL, Rosenwald A, Hurt EM et al.: Signatures of the immune response. Immunity 15, 375-385 (2001).
328. Leen MP, Gorski J: Differential expression of isomorphic HLA-DRβ genes is not a sole function of transcription. Hum. Immunol. 50(2), 111-120 (1996).
329. Stunz LL, Karr RW, Anderson RA: HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level. J. Immunol. 143(9), 3081-3086 (1989).
330. Baharav E, Weinberger A, Mor F: Experimental models of Behçet's disease. Drug Discovery Today: Disease Models 3(1), 11-14 (2006).
331. Friese MA, Jensen LT, Willcox N, Fugger L: Humanized mouse models for organ-specific autoimmune diseases. Curr. Opin. Immunol. 18, 704-709 (2006).
332. Griffiths MM, Encinas JA, Remmers EF, Kuchroo VK, Wilder RL: Mapping autoimmunity genes. Curr. Opin. Immunol. 11, 689-700 (1999).
333. Gregersen JW, Holmes S, Fugger L: Humanized animal models for autoimmune diseases. Tissue Antigens 63(5), 383-394 (2004).
334. Taneja V, David CS: HLA class II transgenic mice as models of human diseases. Immunol. Rev. 169, 67-79 (1999).
335. Matricardi PM, Bonini S: Mimicking microbial 'education' of the immune system: a strategy to revert the epidemic trend of atopy and allergic asthma. Respir. Res. 1, 129-132 (2000).
336. Ewald H, Mortensen PB, Mors O: Decreased risk of acute appendicitis in patients with schizophrenia or manic-depressive psychosis. Schizophr. Res. 49, 287-293 (2001).
337. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP: Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology 43, 790-794 (2004).
338. Kelly D, King T, Aminov R: Importance of microbial colonization of the gut in early life to the development of immunity. Mutat. Res. 622, 58-69 (2007).
339. Petrovsky N, Brusic V. Bioinformatics for study of autoimmunity. Autoimmunity 39(8), 635-643 (2006).
340. Jurrmann N, Brigelius-Flohé R, Böl GF: Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J. Nutr. 135, 1859-1864 (2005).
341. Tur E, Brenner S: Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch. Dermatol. 134, 1406-1410 (1998).
342. Cantorna MT: Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence. Proc. Soc. Exp. Biol. Med. 223(3), 230-233 (2000).
343. Kong J, Grando SA, Li YC: Regulation of IL-1 family cytokines IL-1α, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D3 in primary keratinocytes. J. Immunol. 176, 3780-3787 (2006).
344. Han SN, Meydani SN: Impact of vitamin E on immune function and its clinical implications. Expert Rev. Clin. Immunol. 2(4), 561-567 (2006).
345. Jönsen A, Bengtsson AA, Nived O, Truedsson L, Sturfelt G: Gene-environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity 40(8), 613-617 (2007).
346. Liu EH, Siegel RM, Harlan DM, O'Shea JJ: T cell-directed therapies: lessons learned and future prospects. Nat. Immunol. 8(1), 25-30 (2007).
347. Gemma R, Suda T, Nakamura H: [Immunoregulatory genes in autoimmune thyroid-disease]. Nippon Rinsho. 57(8), 1737-1742 (1999).
348. Lipsker D, Saurat JH: Neutrophilic cutaneous lupus erythematosus at the edge between innate and acquired immunity? Dermatology 216, 283-286 (2008).
349. Scully C, Cawson RA: Medical Problems in Dentistry (5th Edition). Elsevier, London, UK (2005).
350. Marsh SG, Albert ED, Bodmer WF et al.: Nomenclature for factors of the HLA system, 2004. Tissue Antigens 65(4), 301-369 (2005).
351. Middleton D, Menchaca L, Rood H, Komerofsky R: New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61(5), 403-407 (2003).
352. Mobini N, Ahmed AR: Immunogenetics of drug-induced bullous diseases. Clin. Dermatol. 11(4), 449-460 (1993).
353. Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18, 99-107 (2008).
354. Roujeau JC, Huynh TN, Bracq C et al.: Genetic susceptibility to toxic epidermal necrolysis. Arch. Dermatol. 123(9), 1171-1173 (1987).
355. Chung W, Hung S, Hong H et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
356. Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K: The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J. Clin. Invest. 92(3), 1296-1301 (1993).
357. Garlepp MJ: Immunogenetics of inflammatory myopathies. Baillieres Clin. Neurol. 2(3), 579-597 (1993).
358. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL: HLA associations with inclusion body myositis. Clin. Exp. Immunol. 98(1), 40-45 (1994).
359. Ishihara M, Ishida T, Mizuki N, Inoko H, Ando H, Ohno S: Clinical features of sarcoidosis in relation to HLA distribution and HLA-DRB3 genotyping by PCR-RFLP. Br. J. Ophthalmol. 79(4), 322-325 (1995).
360. Smikie MF, Pascoe RW, Barton E et al.: HLA-DRB3*0101 is associated with Graves' disease in Jamaicans. Clin. Endocrinol. 55(6), 805-808 (2001).
361. Grunewald J, Berlin M, Olerup O, Eklund A: Lung T-helper cells expressing T-cell receptor AV2S3 associate with clinical features of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 161(3 Pt 1), 814-818 (2000).
362. Bogunia-Kubik K, Tomeczko, J, Suchnicki K, Lange A: HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens 57(1), 87-90 (2001).
363. Zabay J, Marco J, Soler J et al.: Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain). J. Hum. Hypertens. 19(8), 615-622 (2005).
364. On H, Kwon S, Kim C et al.: Molecular analysis of HLA class II-associated susceptibility to neuroinflammatory diseases in Korean children. J. Korean Med. Sci. 19(3), 426-430 (2004).
365. Galeazzi M, Sebastiani G, Tincani A et al.: HLA class II alleles associations of anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 9(1), 47-55 (2000).
366. Cariappa A, Sands B, Forcione D et al.: Analysis of MHC class II DP, DQ and DR alletes in Crohn's disease. Gut 43(2), 210-215 (1998).
367. Greenspan NS: Conceptualizing immune responsiveness. Nat. Immunol. 8(1), 5-7 (2007).